Host-Microbe Co-metabolism Dictates Cancer Drug Efficacy in C. elegans

Fluoropyrimidines are the first-line treatment for colorectal cancer, but their efficacy is highly variable between patients. We queried whether gut microbes, a known source of inter-individual variability, impacted drug efficacy. Combining two tractable genetic models, the bacterium E. coli and the...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cell 2017-04, Vol.169 (3), p.442-456.e18
Hauptverfasser:	Scott, Timothy A., Quintaneiro, Leonor M., Norvaisas, Povilas, Lui, Prudence P., Wilson, Matthew P., Leung, Kit-Yi, Herrera-Dominguez, Lucia, Sudiwala, Sonia, Pessia, Alberto, Clayton, Peter T., Bryson, Kevin, Velagapudi, Vidya, Mills, Philippa B., Typas, Athanasios, Greene, Nicholas D.E., Cabreiro, Filipe
Format:	Artikel
Sprache:	eng
Schlagworte:	5-FU Animals Antineoplastic Agents - metabolism Autophagy bacteria C. elegans Caenorhabditis elegans cancer Cell Death chemical-genomics co-metabolism colorectal neoplasms Colorectal Neoplasms - drug therapy Diet drugs E. coli Escherichia coli Escherichia coli - enzymology Escherichia coli - genetics Escherichia coli - metabolism Fluorouracil - metabolism Gastrointestinal Microbiome genetic models holobiont Humans intestinal microorganisms Keio metabolism Models, Animal Nematoda nucleoside-diphosphate kinase nucleotide metabolism patients Pentosyltransferases - genetics pyridoxine
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!